These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30025214)

  • 21. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
    Schaeffer T
    J Med Toxicol; 2012 Dec; 8(4):400-7. PubMed ID: 23073726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.
    Cassidy TA; Oyedele N; Mickle TC; Guenther S; Budman SH
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1071-1082. PubMed ID: 28771942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.
    Webster L; St Marie B; McCarberg B; Passik SD; Panchal SJ; Voth E
    J Opioid Manag; 2011; 7(3):235-45. PubMed ID: 21823554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
    Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R
    Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An overview of abuse-deterrent opioids and recommendations for practical patient care.
    Adler JA; Mallick-Searle T
    J Multidiscip Healthc; 2018; 11():323-332. PubMed ID: 30026658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.
    Altomare C; Kinzler ER; Buchhalter AR; Cone EJ; Costantino A
    J Opioid Manag; 2017; 13(6):441-448. PubMed ID: 29308590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
    Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic burden of prescription opioid misuse and abuse.
    Strassels SA
    J Manag Care Pharm; 2009 Sep; 15(7):556-62. PubMed ID: 19739878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
    Stanos SP; Bruckenthal P; Barkin RL
    Mayo Clin Proc; 2012 Jul; 87(7):683-94. PubMed ID: 22766088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.